Ehime University Graduate School of Medicine, Department of Bioregulatory Medicine, Shitsukawa, Toon, Ehime 791-0295, Japan.
Expert Opin Ther Targets. 2009 Dec;13(12):1399-410. doi: 10.1517/14728220903307483.
Although cellular immunotherapy still remains in its infancy, it is one of the important treatment options against cancer. The marked improvement of its clinical efficacy requires a 'better' target antigen, which is well recognized by cancer-cell-specific cytotoxic T lymphocytes. We have recently demonstrated the potential of Aurora-A kinase (Aurora-A) as such a 'better' target for cellular immunotherapy against human leukemia. Aurora-A is a member of the serine/threonine kinase family that properly regulates the cell division process, and has recently been implicated in tumorigenesis. On the other hand, small-molecule inhibitors targeting Aurora-A have recently been developed and preliminary but promising observations from Phase I clinical trials have been reported. These facts highlight the attractiveness of Aurora-A as an important target of comprehensive cancer therapies.
OBJECTIVE/METHODS: In this review, we cover Aurora-A in the areas of immunotherapy and small-molecule inhibitor therapy against cancers.
RESULTS/CONCLUSIONS: Aurora-A kinase is an attractive molecule not only as a target for small-molecule inhibitors, but also as a potential target for immunotherapy against cancer.
尽管细胞免疫疗法仍处于起步阶段，但它是对抗癌症的重要治疗选择之一。其临床疗效的显著提高需要一个“更好”的靶抗原，该抗原能被肿瘤细胞特异性细胞毒性 T 淋巴细胞很好地识别。我们最近证明了 Aurora-A 激酶（Aurora-A）作为细胞免疫疗法治疗人类白血病的“更好”靶标的潜力。Aurora-A 是丝氨酸/苏氨酸激酶家族的成员，能适当调节细胞分裂过程，最近已被牵连到肿瘤发生中。另一方面，针对 Aurora-A 的小分子抑制剂已被开发出来，并且已报道了来自 I 期临床试验的初步但有希望的观察结果。这些事实突出了 Aurora-A 作为综合癌症治疗的重要靶标具有吸引力。
目的/方法：在这篇综述中，我们涵盖了 Aurora-A 在癌症的免疫治疗和小分子抑制剂治疗领域的作用。
结果/结论：Aurora-A 激酶不仅是小分子抑制剂的一个有吸引力的靶标，也是癌症免疫治疗的一个潜在靶标。
